Navicixizumab
From EverybodyWiki Bios & Wiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Chimeric/humanized hybrid (mouse/human) |
| Target | DLL4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C6481H9981N1719O2030S54 |
| Molar mass | 145.9 g/mol g·mol−1 |
Navicixizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of cancer.
This drug was developed by OncoMed Pharmaceuticals Inc.[2]
References[edit]
 | This monoclonal antibody–related article is a stub. You can help EverybodyWiki by expanding it. |
This article "Navicixizumab" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
